Abstract | PURPOSE: METHODS: RESULTS:
Anecortave acetate 15 mg was statistically superior to vehicle in the monotherapy trial at both 12 and 24 months for maintenance of vision and inhibition of CNV lesion growth. In the combination trial, a trend favored adding either anecortave acetate 15 mg or 30 mg to PDT for these two measures of clinical efficacy, but this short-duration study did not achieve statistical significance. Anecortave acetate 15 mg is comparable to PDT for maintaining vision over the 24-month period in the comparison trial. CONCLUSIONS:
|
Authors | Stephen R Russell, Henry L Hudson, Janice A Jerdan, Anecortave Acetate Clinical Study Group |
Journal | Survey of ophthalmology
(Surv Ophthalmol)
Vol. 52 Suppl 1
Pg. S79-90
(Jan 2007)
ISSN: 0039-6257 [Print] United States |
PMID | 17240260
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Pregnadienediols
- anecortave acetate
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Choroidal Neovascularization
(drug therapy)
- Clinical Trials as Topic
- Exudates and Transudates
- Humans
- Macular Degeneration
(drug therapy)
- Pregnadienediols
(therapeutic use)
- Treatment Outcome
|